View Older Stories View More Recent Stories
-
Goldman rolls out latest U.S. Conviction List update
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $377 at Needham
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $360 at BMO Capital
-
Alnylam Pharma (ALNY) names Pushkal Garg as Chief Research and Development Officer
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): 'Amvuttra Survey Suggests 2Q Beat'
-
Instil Bio Inc. (TIL) Appoints John Maraganore to its Board
-
Alnylam Pharma (ALNY) Receives EU Approval for AMVUTTRA
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): 'HQ Visit Makes Us More Positive About The Q'
-
JPMorgan Reiterates Overweight Rating on Alnylam Pharmaceuticals (ALNY)
-
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) Tops Q1 EPS by 92c
-
Alnylam Pharma (ALNY) Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Piper Sandler: 'What Biotech Names to Own in Market Volatility'
-
Bernstein Recommends Three US Biotech Stocks Amid 'Heightened Regulatory Uncertainty'
-
Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Stifel Raises Price Target on Alnylam Pharmaceuticals (ALNY) to $345
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $342 at Scotiabank
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $345 at Stifel
-
Redburn-Atlantic Starts Alnylam Pharmaceuticals (ALNY) at Buy
-
Alnylam Pharma (ALNY) Announces FDA Approval of Qfitlia
-
Bernstein on Alnylam Pharmaceuticals (ALNY): 'A Strident but Unconvincing Bear Case'
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): 'Incrementally More Positive on ALNY and Remain Buyers'
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
JPMorgan Upgrades Alnylam Pharmaceuticals (ALNY) to Overweight
-
Alnylam Pharma (ALNY) call put ratio 1.9 calls to 1 put on 7500 contracts as share price up 10%
-
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $338 at Scotiabank
-
Cantor Fitzgerald Reiterates Neutral Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $390 at Canaccord Genuity
-
Alnylam Pharma (ALNY) announces FDA approval of AMVUTTRA
-
Alnylam Pharma (ALNY) Halted, News Pending
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
Alnylam Pharma (ALNY) Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
RBC on Alnylam Pharmaceuticals (ALNY): 'We Would Be Buyers Ahead Of Upcoming PDUFA Date'
-
Piper Sandler Reiterates Overweight on Alnylam Pharmaceuticals (ALNY), 'Confident in AMVUTTRA Approval'
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $500 at H.C. Wainwright
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $385 at Canaccord Genuity
-
Alnylam Pharma (ALNY) Tops Q4 EPS by 64c ; Offers Guidance
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): 'Our Expert Sees A Favorable Set-up'
-
Goldman Makes Monthly Adjustment to Director's Cut Conviction List
-
H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) After a Solid TTR Beat
-
Alnylam Pharma (ALNY) Announces Preliminary Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance
-
Barclays shares outlook for Biotech in 2025, names preferred stocks

